Recently, teplizumab proved to be efficacious in delaying the onset of overt diabetes in a subgroup of beta cell autoantibody-positive individuals with dysglycaemia [24], providing evidence of the first immune intervention able to delay the diagnosis of diabetes and the requirement for insulin treatment. Here, INS is linked to diabetes mellitus.